Building Hope.

Trovagene is developing precision cancer therapeutics to improve cancer care.

Our Mission

Our mission is to transform cancer therapeutics to improve cancer care.

Our Therapeutics

We are a clinical stage precision medicine biotechnology company developing oncology therapeutics for hematologic and solid tumor cancers. Beginning with our lead drug candidate PCM-075, a Polo-like Kinase 1 (PLK1) Inhibitor, we are on a journey to develop new treatment options to help transform cancer care.

PCM-075 is the first PLK1 inhibitor of its kind to enter clinical trials. Now with the FDA’s granting of orphan drug designation for PCM-075 to treat patients with Acute Myeloid Leukemia (AML), and initiation of our Phase 1b/2 clinical trial, we are moving forward with our clinical development program.

We optimize drug development by leveraging our significant experience and expertise in biomarker and Precision Cancer Medicine® (PCM) technology to address the need for new therapeutic options to treat hematologic and solid tumor cancers.

What is PCM-075, a PLK1 Inhibitor?

PCM-075 is the first PLK1 inhibitor of its kind to enter clinical trials. It is an oral, highly selective competitive inhibitor of the PLK1 enzyme which is commonly overexpressed in several different hematologic and solid tumor cancers.

These attributes combined with potential synergy in combination with numerous chemotherapeutics and targeted therapies makes PCM-075 a highly attractive drug candidate.

Orphan Drug Designation in AML

On September 28th, 2017, the FDA granted Orphan Drug Designation to our PLK1 inhibitor, PCM-075 for the treatment of Acute Myeloid Leukemia, an important milestone in our clinical development plan.

PCM-075 Clinical Evidence

PCM-075 has the potential to be a safe and effective treatment for hematologic and solid tumor cancers due to high selectivity for PLK1, relatively short half-life, and more.

Combination Therapy Opportunities

PCM-075 may be synergistic and enhance the efficacy of current and future standard-of-care therapies.

In Our Pipeline

We are developing PCM-075 for both hematologic and solid tumor cancers. Our Precision Cancer Medicine® technology allows us to measure genetic fragments of cancer tumors to identify patients most likely to respond to therapy.

News

Dec 7, 2017

Trovagene Presents Data Showing Sensitivity of Triple Negative Breast Cancer (TNBC) Cell Lines to PCM-075 and Synergy with Zytiga® at San Antonio Breast Cancer Symposium (SABCS)

Trovagene, Inc. (NASDAQ: TROV), a precision medicine biotechnology company, today announced that preclinical data demonstrating the sensitivity of triple negative breast cancer (TNBC) cell lines…

Learn More

Nov 13, 2017

Trovagene Announces Activation of First Clinical Trial Site in Phase 1b/2 Acute Myeloid Leukemia (AML) Trial for PCM-075

Trovagene, Inc. (NASDAQ: TROV), a precision medicine biotechnology company, today announced the activation of its clinical trial site for its Phase 1b/2 multicenter trial of PCM-075 in patients…

Nov 9, 2017

Trovagene Announces Third Quarter 2017 Company Highlights and Financial Results

Trovagene, Inc. (NASDAQ: TROV), a clinical-stage precision medicine biotechnology company, today announced company highlights and financial results for the third quarter ended September 30, 2017…